Research programme: glycoprotein therapeutics - Boston Therapeutics

Drug Profile

Research programme: glycoprotein therapeutics - Boston Therapeutics

Alternative Names: Ipoxyn

Latest Information Update: 30 May 2014

Price : $50

At a glance

  • Originator Boston Therapeutics
  • Class Glycoproteins
  • Mechanism of Action Oxygen carriers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anaemia; Cardiovascular disorders; Peripheral ischaemia

Most Recent Events

  • 30 May 2014 Preclinical development is ongoing
  • 27 Mar 2013 Boston Therapeutics announces its intention to accelerate the development of Ipoxyn™ in lower limb ischaemia associated with diabetes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top